Is TWST a good stock to buy?
Twist Bioscience Corporation · end-of-day data as of Nov 13, 2026
- PT$145.70 +30.6%
- ConsensusBuy · 13
- Sector▲ +15.9%
- Earnings in80d
- RSI38
- Support-50.2%
- Resistance+55.4%
- Off 52w high-49.2%
- Volume0.8x
- Bollingerlower half
- News1.00
- Trendsideways
- 52w range$23–$220
- ATR+15.1%
- Off ATH-49.2%
- Insiders-$99.86M
- MAs1 of 4
- MA20×50Death 9d ago
- MACD-3.21
Updates with the 15-min delayed price. Not a forecast or investment advice.
Is Twist Bioscience a good stock to buy?
Twist Bioscience is strong on 2 of the 5 questions about the business; weak on advantage, economics and execution. With a loss over the last 12 months, Twist Bioscience has no P/E ratio (Nov 13, 2026). pretickt does not say whether to buy or sell.
- Demand growing
- Advantage easy to copy
- Economics losing money
- Execution misses
- Fragility sturdy
- Price like its peers
TWST sales growth revenue growth
+23%a year, for the last 3 yearsTwist Bioscience's sales grew 23% a year for 3 years, to $459M in fiscal 2026.
TWST analysts' forecast revenue estimates
+19%the sales they expect next fiscal year, on the lastAnalysts expect Twist Bioscience's sales to grow 19% to $549M in fiscal 2027 (8 analysts).
TWST competitors
pretickt analysis+22%its sales in 12 months, on a year before
Twist Bioscience's sales grew 22% in the 12 months to Sep 30, 2026, faster than Bio-Techne (+1%) and CRISPR Therapeutics (-33%), slower than Alnylam (+56%) and Incyte (+25%).
TWST sales by business revenue by segment
55%of its sales from Ngs ToolsNgs Tools brought Twist Bioscience 55% of its sales in fiscal 2025; Synthetic Genes 30%.
TWST return on capital ROIC
pretickt analysis-31%earned before tax on the money invested in itTwist Bioscience earned -31% before tax on the capital invested in it in the 12 months to Sep 30, 2026; Alnylam 31%, Incyte 29%, Bio-Techne 11% and CRISPR Therapeutics -24%.
TWST margin on each sale gross margin
52%left after making the productTwist Bioscience kept 52% of each sale after making the product in the 12 months to Sep 30, 2026; its competitors' median is 72%.
TWST margin after costs profit margin
-30%of sales left after running the businessTwist Bioscience's operating margin was -30% in the 12 months to Sep 30, 2026, against -89% in fiscal 2023.
TWST earnings vs estimates
3 of 6quarters above the analysts' estimateTwist Bioscience beat the analysts' profit estimate in 3 of 6 quarters, the latest on Aug 3, 2026; 2 quarters the sources disagree on are left out.
TWST insider selling
-$148Msold, net, by its executives in 12 monthsTwist Bioscience's executives and directors sold a net $148M of shares in the 12 months to Nov 13, 2026; none bought.
TWST number of employees
+6%more people in a yearTwist Bioscience had 979 employees at the end of fiscal 2025, 6% more than a year before.
TWST CEO pay
$13.78Mfor fiscal 2025, 87% of it in stock and optionsTwist Bioscience paid its CEO $13.78M for fiscal 2025, 87% of it in stock and options.
TWST financial health Altman Z-score
20.0Altman Z-score, safe above 3Twist Bioscience's Altman Z-score is 20.0 (Nov 13, 2026), above 3, where the safe zone starts.
TWST price vs profit P/E ratio
—it lost money in 12 months: no P/ETwist Bioscience has no P/E ratio: it lost money over the 12 months to Sep 30, 2026.
TWST price vs assets price to book
8.3×times what its assets are worth on paperTwist Bioscience trades at 8.3 times its book value (Nov 13, 2026); its competitors' median is 4.8.
TWST analysts' target price target
+31%to their average targetAnalysts' average price target for Twist Bioscience is $146, 31% above the Nov 13, 2026 close of $111.60.
What is Twist Bioscience's P/E ratio?
Twist Bioscience has no P/E ratio: it lost money over the 12 months to Sep 30, 2026. Twist Bioscience trades at 8.3 times its book value (Nov 13, 2026); its competitors' median is 4.8.
Who are Twist Bioscience's biggest competitors?
pretickt compares Twist Bioscience with Bio-Techne, CRISPR Therapeutics, Alnylam and Incyte. Twist Bioscience's sales grew 22% in the 12 months to Sep 30, 2026, faster than Bio-Techne (+1%) and CRISPR Therapeutics (-33%), slower than Alnylam (+56%) and Incyte (+25%).
Is Twist Bioscience profitable?
Twist Bioscience's operating margin was -30% in the 12 months to Sep 30, 2026, against -89% in fiscal 2023.
Who is dumping Twist Bioscience stock?
Twist Bioscience's executives and directors sold a net $148M of shares in the 12 months to Nov 13, 2026; none bought.
How does Twist Bioscience make money?
Ngs Tools brought Twist Bioscience 55% of its sales in fiscal 2025; Synthetic Genes 30%.
How many employees does Twist Bioscience have?
Twist Bioscience had 979 employees at the end of fiscal 2025, 6% more than a year before.
From the companies' statements (FMP), their filings read by pretickt, the analysts and the insiders, as of Nov 13, 2026. Each card says what a fact means for its question, never what to do with the stock: for information only, not investment advice.